⏱️ Low-Carb vs Mediterranean Diet Cardiometabolic Marker Comparator

Baseline Cardiometabolic Markers

Both diets start from matched baseline risk profiles.

• 130 mg/dL: LDL cholesterol (typical trial entry)
• 45 mg/dL: HDL cholesterol (matched cohorts)
• 105 mg/dL: Fasting glucose (prediabetic range)
• 12 months: Trial duration (standard comparison window)

Randomized trial design

Participants matched for weight, age, and baseline labs.

Why baseline matters

Identical starting points isolate true diet effects.

Tracking method

Markers reassessed at 3, 6, and 12 months.

Baseline equivalence isolates diet effects from confounding factors.

3-Month Lipid Panel Divergence

Low-carb lifts LDL faster than Mediterranean early on.

• +12%: LDL change, low-carb (3-month rise)
• -2%: LDL change, Mediterranean (3-month change)
• +4%: HDL change, low-carb (modest early gain)
• +6%: HDL change, Mediterranean (steadier early gain)

Saturated fat intake

Low-carb diets often raise saturated fat consumption.

Olive oil effect

Mediterranean olive oil favors healthier lipid particles.

Particle size nuance

Low-carb LDL particles may shift toward a benign subtype.

LDL rise on low-carb doesn't always signal higher cardiovascular risk.

Glycemic Control Comparison

Low-carb drops glucose faster in the short term.

• -18%: Glucose, low-carb 3mo (rapid short-term drop)
• -10%: Glucose, Mediterranean 3mo (gradual short-term drop)
• -0.6 pt: HbA1c, low-carb (absolute change)
• -0.3 pt: HbA1c, Mediterranean (absolute change)

Carbohydrate restriction

Fewer carbs directly lowers post-meal glucose spikes.

Insulin sensitivity

Mediterranean improves insulin sensitivity more gradually.

Durability question

Low-carb's early glucose edge often narrows by month twelve.

Short-term glucose gains don't always predict long-term diabetes outcomes.

Cardiovascular Marker Trends

Mediterranean shows stronger long-term cardiovascular outcome evidence.

• -5%: CV risk marker, low-carb (12-month composite)
• -18%: CV risk marker, Mediterranean (12-month composite)
• -30%: Major CV events (PREDIMED) (relative risk reduction)
• -20%: hs-CRP, Mediterranean (inflammation marker drop)

PREDIMED trial evidence

Landmark trial linked Mediterranean diet to fewer CV events.

Inflammation pathway

Polyphenols and omega-3s lower systemic inflammation markers.

Low-carb CV data gap

Long-term low-carb cardiovascular outcome trials remain limited.

Mediterranean diet carries the strongest hard-outcome trial evidence to date.

12-Month Comparative Outcomes

Both diets improve markers with different risk tradeoffs.

• +8%: LDL change, low-carb (12-month value)
• -6%: LDL change, Mediterranean (12-month value)
• +14%: HDL change, Mediterranean (12-month value)
• -15%: Glucose change, low-carb (12-month value)

Choosing a diet

Individual risk profile should guide diet selection.

Combining strengths

Low-carb glycemic gains plus Mediterranean lipid safety may work.

Clinical takeaway

Both diets beat standard low-fat advice in trials.

No single diet wins every cardiometabolic marker outcome.